Drugs / HNF4α srRNA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06621173 | Nov 2024 → Jul 2026 overdue | colorectal cancer | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06583993 | Nov 2024 → May 2026 overdue | intrahepatic cholangiocarcinoma | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HNF4α srRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06621173 ↗ |
| Known as | CD-801 | “the safety/efficacy data of HNF4α srRNA (CD-801/CD-GA-102) administered via peripheral vein for hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), or...” NCT06621173 ↗1“the HNF4α srRNA preparation CD-801 used in the original protocol will expire on December 31, 2024.” NCT06583993 ↗ |
| Known as | CD-GA-102 | “the safety/efficacy data of HNF4α srRNA (CD-801/CD-GA-102) administered via peripheral vein for hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), or...” NCT06621173 ↗ |
| Action | Activate | “facilitate the expression of HNF4α” NCT06583993 ↗ |
| Route | Intravenous | “HNF4α srRNA will be administered intravenously for the treatment of ICC.” NCT06583993 ↗ |